6OBD
Crystal structure of anti-GLD52 Fab complex with human GLD52 peptide mimetic
6OBD の概要
| エントリーDOI | 10.2210/pdb6obd/pdb |
| 分子名称 | anti-GLD52 Fab light chain, anti-GLD52 Fab heavy chain, GLD52 peptide mimetic, ... (6 entities in total) |
| 機能のキーワード | fab, gld52, immune system |
| 由来する生物種 | Mus musculus (Mouse) 詳細 |
| タンパク質・核酸の鎖数 | 6 |
| 化学式量合計 | 96053.57 |
| 構造登録者 | |
| 主引用文献 | Qiu, H.,Wei, R.,Jaworski, J.,Boudanova, E.,Hughes, H.,VanPatten, S.,Lund, A.,Day, J.,Zhou, Y.,McSherry, T.,Pan, C.Q.,Sendak, R. Engineering an anti-CD52 antibody for enhanced deamidation stability. Mabs, 11:1266-1275, 2019 Cited by PubMed Abstract: Deamidation evaluation and mitigation is an important aspect of therapeutic antibody developability assessment. We investigated the structure and function of the Asn-Gly deamidation in a human anti-CD52 IgG1 antibody light chain complementarity-determining region 1, and risk mitigation through protein engineering. Antigen binding affinity was found to decrease about 400-fold when Asn was replaced with an Asp residue to mimic the deamidation product, suggesting significant impacts on antibody function. Other variants made at Asn (N33H, N33Q, N33H, N33R) were also found to result in significant loss of antigen binding affinity. The co-crystal structure of the antigen-binding fragment bound to a CD52 peptide mimetic was solved at 2.2Å (PDB code 6OBD), which revealed that Asn directly interacts with the CD52 phosphate group via a hydrogen bond. Gly, but sits away from the binding interface, rendering it more amendable to mutagenesis without affecting affinity. Saturation mutants at Gly were prepared and subjected to forced deamidation by incubation at elevated pH and temperature. Three mutants (G34R, G34K and G34Q) showed increased resistance to deamidation by LC-MS peptide mapping, while maintaining high binding affinity to CD52 antigen measured by Biacore. A complement -dependent cytotoxicity assay indicated that these mutants function by triggering antibody effector function. This study illustrates the importance of structure-based design and extensive mutagenesis to mitigate antibody developability issues. PubMed: 31199181DOI: 10.1080/19420862.2019.1631117 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






